After the 4-h management of the BD donor, those that received GC7 therapy showed a decreased generation of ROS and markers induced by BD, as well as an upregulation of the expression of mitochondrial biogenesis protein, PGC1-α (17). The gene discussed is PPARGC1A; the disease is Behcet disease.